San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

Patients with metastatic breast cancer prefer oral endocrine therapy because of convenience, while healthcare providers recognize the benefits of oral and intramuscular options. Read More ›

Imlunestrant, a novel oral SERD, demonstrates promising efficacy and safety in a phase 3 trial for advanced breast cancer patients. Read More ›

Early results from the SERENA-1 trial show camizestrant combined with ribociclib may be safe and effective for treating estrogen receptor–positive/HER2-negative advanced breast cancer. Read More ›

A new study shows promising real-world results for elacestrant in advanced breast cancer patients with ESR1 mutations, exceeding prior clinical trial data. Read More ›

Ongoing trials suggest that combining elacestrant with other therapies may offer a safe and effective treatment option for estrogen receptor–positive/HER2-negative metastatic breast cancer. Read More ›

While SERDs have a storied history, advancements of newer agents like elacestrant and imlunestrant have been successful in overcoming limitations of older treatments Read More ›

Liquid biopsy using ctDNA analysis is transforming breast cancer care, offering potential for personalized treatment, early detection, and monitoring response. Read More ›

The PADMA phase 3 trial demonstrated that combining palbociclib with endocrine therapy significantly outperformed standard chemotherapy in treating high-risk HR-positive/HER2-negative metastatic breast cancer. Read More ›

The DESTINY-Breast06 phase 3 trial showed that trastuzumab deruxtecan significantly improved progression-free survival in HR-positive, HER2-low, HER2-ultralow metastatic breast cancer. Read More ›

The SOLTI VALENTINE phase 2 study explored HER3-DXd as a promising treatment for high-risk HR-positive/HER2-negative early breast cancer, showing the therapy’s ability to induce strong immune responses. Read More ›

Page 4 of 16

Conference Coverage Proudly Presented by
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications